These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 21245486)
1. NK314 potentiates antitumor activity with adult T-cell leukemia-lymphoma cells by inhibition of dual targets on topoisomerase II{alpha} and DNA-dependent protein kinase. Hisatomi T; Sueoka-Aragane N; Sato A; Tomimasu R; Ide M; Kurimasa A; Okamoto K; Kimura S; Sueoka E Blood; 2011 Mar; 117(13):3575-84. PubMed ID: 21245486 [TBL] [Abstract][Full Text] [Related]
2. NK314, a topoisomerase II inhibitor that specifically targets the alpha isoform. Toyoda E; Kagaya S; Cowell IG; Kurosawa A; Kamoshita K; Nishikawa K; Iiizumi S; Koyama H; Austin CA; Adachi N J Biol Chem; 2008 Aug; 283(35):23711-20. PubMed ID: 18596031 [TBL] [Abstract][Full Text] [Related]
3. NK314, a novel topoisomerase II inhibitor, induces rapid DNA double-strand breaks and exhibits superior antitumor effects against tumors resistant to other topoisomerase II inhibitors. Onda T; Toyoda E; Miyazaki O; Seno C; Kagaya S; Okamoto K; Nishikawa K Cancer Lett; 2008 Jan; 259(1):99-110. PubMed ID: 17998154 [TBL] [Abstract][Full Text] [Related]
4. DNA-dependent protein kinase and ataxia telangiectasia mutated (ATM) promote cell survival in response to NK314, a topoisomerase IIα inhibitor. Guo L; Liu X; Jiang Y; Nishikawa K; Plunkett W Mol Pharmacol; 2011 Aug; 80(2):321-7. PubMed ID: 21546556 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of DNA-PK potentiates the synergistic effect of NK314 and etoposide combination on human glioblastoma cells. Kopa P; Macieja A; Gulbas I; Pastwa E; Poplawski T Mol Biol Rep; 2020 Jan; 47(1):67-76. PubMed ID: 31583565 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of topoisomerase IIalpha and G2 cell cycle arrest by NK314, a novel benzo[c]phenanthridine currently in clinical trials. Guo L; Liu X; Nishikawa K; Plunkett W Mol Cancer Ther; 2007 May; 6(5):1501-8. PubMed ID: 17513599 [TBL] [Abstract][Full Text] [Related]
7. Targeting of AKT1 enhances radiation toxicity of human tumor cells by inhibiting DNA-PKcs-dependent DNA double-strand break repair. Toulany M; Kehlbach R; Florczak U; Sak A; Wang S; Chen J; Lobrich M; Rodemann HP Mol Cancer Ther; 2008 Jul; 7(7):1772-81. PubMed ID: 18644989 [TBL] [Abstract][Full Text] [Related]
8. DNA-PKcs deficiency inhibits glioblastoma cell-derived angiogenesis after ionizing radiation. Liu Y; Zhang L; Liu Y; Sun C; Zhang H; Miao G; Di CX; Zhou X; Zhou R; Wang Z J Cell Physiol; 2015 May; 230(5):1094-103. PubMed ID: 25294801 [TBL] [Abstract][Full Text] [Related]
10. The polyphenolic ellagitannin vescalagin acts as a preferential catalytic inhibitor of the α isoform of human DNA topoisomerase II. Auzanneau C; Montaudon D; Jacquet R; Puyo S; Pouységu L; Deffieux D; Elkaoukabi-Chaibi A; De Giorgi F; Ichas F; Quideau S; Pourquier P Mol Pharmacol; 2012 Jul; 82(1):134-41. PubMed ID: 22528119 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of the DNA-dependent protein kinase catalytic subunit radiosensitizes malignant glioma cells by inducing autophagy. Daido S; Yamamoto A; Fujiwara K; Sawaya R; Kondo S; Kondo Y Cancer Res; 2005 May; 65(10):4368-75. PubMed ID: 15899829 [TBL] [Abstract][Full Text] [Related]
12. The dual topoisomerase inhibitor A35 preferentially and specially targets topoisomerase 2α by enhancing pre-strand and post-strand cleavage and inhibiting DNA religation. Zhao W; Jiang G; Bi C; Li Y; Liu J; Ye C; He H; Li L; Song D; Shao R Oncotarget; 2015 Nov; 6(35):37871-94. PubMed ID: 26462155 [TBL] [Abstract][Full Text] [Related]
13. Echinoside A, a new marine-derived anticancer saponin, targets topoisomerase2alpha by unique interference with its DNA binding and catalytic cycle. Li M; Miao ZH; Chen Z; Chen Q; Gui M; Lin LP; Sun P; Yi YH; Ding J Ann Oncol; 2010 Mar; 21(3):597-607. PubMed ID: 19773249 [TBL] [Abstract][Full Text] [Related]
14. Comparison of the effect of three different topoisomerase II inhibitors combined with cisplatin in human glioblastoma cells sensitized with double strand break repair inhibitors. Macieja A; Kopa P; Galita G; Pastwa E; Majsterek I; Poplawski T Mol Biol Rep; 2019 Aug; 46(4):3625-3636. PubMed ID: 31020489 [TBL] [Abstract][Full Text] [Related]
15. Inhibiting DNA-PKcs in a non-homologous end-joining pathway in response to DNA double-strand breaks. Dong J; Zhang T; Ren Y; Wang Z; Ling CC; He F; Li GC; Wang C; Wen B Oncotarget; 2017 Apr; 8(14):22662-22673. PubMed ID: 28186989 [TBL] [Abstract][Full Text] [Related]
16. Chemosensitization of cancer cells by KU-0060648, a dual inhibitor of DNA-PK and PI-3K. Munck JM; Batey MA; Zhao Y; Jenkins H; Richardson CJ; Cano C; Tavecchio M; Barbeau J; Bardos J; Cornell L; Griffin RJ; Menear K; Slade A; Thommes P; Martin NM; Newell DR; Smith GC; Curtin NJ Mol Cancer Ther; 2012 Aug; 11(8):1789-98. PubMed ID: 22576130 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of topoisomerase IIα sensitizes FaDu cells to ionizing radiation by diminishing DNA repair. Saleh EM Tumour Biol; 2015 Nov; 36(11):8985-92. PubMed ID: 26081617 [TBL] [Abstract][Full Text] [Related]
18. Suppression of DNA-dependent protein kinase sensitize cells to radiation without affecting DSB repair. Gustafsson AS; Abramenkovs A; Stenerlöw B Mutat Res; 2014 Nov; 769():1-10. PubMed ID: 25771720 [TBL] [Abstract][Full Text] [Related]
19. A cysteine-reactive alkyl hydroquinone modifies topoisomerase IIα, enhances DNA breakage, and induces apoptosis in cancer cells. Lin TY; Huang CP; Au LC; Chang YW; Hu CY; Lin SB Chem Res Toxicol; 2012 Nov; 25(11):2340-51. PubMed ID: 23088786 [TBL] [Abstract][Full Text] [Related]
20. Ethonafide-induced cytotoxicity is mediated by topoisomerase II inhibition in prostate cancer cells. Pourpak A; Landowski TH; Dorr RT J Pharmacol Exp Ther; 2007 Jun; 321(3):1109-17. PubMed ID: 17351106 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]